News Releases | Lexicon Pharmaceuticals, Inc.

Press Releases

Title	Published Date
Lexicon Pharmaceuticals Receives Fast Track Designation from the FDA for LX9211 for Diabetic Peripheral Neuropathic Pain	Dec 11, 2020
Results from Soloist and Scored Outcomes Studies Presented at Late-breaking Science Session of American Heart Association Scientific Sessions and Published in the New England Journal of Medicine	Nov 16, 2020
Lexicon Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference	Nov 16, 2020
Lexicon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical Update	Oct 29, 2020
Lexicon Pharmaceuticals to Host Third Quarter 2020 Financial Results Conference Call and Webcast on October 29, 2020	Oct 27, 2020
Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness	Sep 23, 2020
Lexicon Pharmaceuticals Completes the Sale of Xermelo to TerSera Therapeutics	Sep 08, 2020
Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients with Diabetic Peripheral Neuropathic Pain	Sep 04, 2020
Lexicon Pharmaceuticals to Participate in the Citi 15th Annual Biopharma Virtual Conference and the Wells Fargo 2020 Virtual Healthcare Conference	Sep 03, 2020
Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program	Jul 30, 2020